People · Operator
Named in public records as an officer, director or promoter · active 2015–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tune Therapeutics, Inc. | — | Biotechnology | Series D+ | $182.4M | $3.1B | 2023 |
| Precision Biosciences Inc | — | Biotechnology | Series C | $153.3M | $1.6B | 2015 |
DEREK JANTZ at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DEREK JANTZ on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ali Behbahani | 1 | 17 |
| JEFF SMITH | 1 | 17 |
| Ben Auspitz | 1 | 9 |
| Robert Adelman | 1 | 5 |
| Shalini Sharp | 1 | 4 |
| MATTHEW KANE | 1 | 4 |
| Tony Yao | 1 | 3 |
| Dan McHugh | 1 | 3 |
| Yuan Zhang | 1 | 2 |
| Blythe Sather | 1 | 1 |
| Charles Gersbach | 1 | 1 |
| John McHutchison | 1 | 1 |
| Zachary Hale | 1 | 1 |
| Abid Ansari | 1 | 1 |
| Akira Matsuno | 1 | 1 |
| TODD MELBY | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.